[1] | Siegel R, Ma JM, Zou ZH, Jemal A. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29. | [2] | Perou CM, S?rlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge ?, Pergamenschikov A, Williams C, Zhu SX, L?nning PE, B?rresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752. | [3] | The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70. | [4] | Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov, 2014, 13(1): 63-79. | [5] | Zhao B, Wei XM, Li WQ, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu JD, Li L, Zheng P, Ye KQ, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev, 2007, 21(21): 2747-2761. | [6] | Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao SM, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol, 2008, 28(7): 2426-2436. | [7] | Cui CB, Cooper LF, Yang XL, Karsenty G, Aukhil I. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol, 2003, 23(3): 1004-1013. | [8] | Jeong H, Bae S, An SY, Byun MR, Hwang JH, Yaffe MB, Hong JH, Hwang ES. TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. FASEB J, 2010, 24(9): 3310-3320. | [9] | Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science, 2005, 309(5737): 1074-1078. | [10] | Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem, 2004, 279(17): 17384-17390. | [11] | Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, Asano T, Kurihara H. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun, 2006, 339(2): 533-539. | [12] | Di Palma T, D'Andrea B, Liguori GL, Liguoro A, de Cristofaro T, Del Prete D, Pappalardo A, Mascia A, Zannini M. TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp Cell Res, 2009, 315(2): 162-175. | [13] | Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol, 2008, 10(7): 837-848. |
|
[1] |
马春辉, 胡海旭, 张丽娟, 刘毅, 刘天懿. 用于循环肿瘤细胞定量分析的CK19数字PCR检测方法的建立及性能验证[J]. 遗传, 2023, 45(3): 250-260. |
[2] |
常栋, 刘享享, 刘睿, 孙建伟. FSCN1在乳腺癌发生发展中的作用及其调控机制[J]. 遗传, 2023, 45(2): 115-127. |
[3] |
张强, 顾明亮. 单细胞测序技术及其在乳腺癌研究中的应用[J]. 遗传, 2020, 42(3): 250-268. |
[4] |
王昕源, 张雨, 杨楠, 程禾, 孙玉洁. DNMT3a通过提升基因内部甲基化介导紫杉醇诱导的LINE-1异常表达[J]. 遗传, 2020, 42(1): 100-111. |
[5] |
禹奇超,宋彬,邹轩轩,王岭,刘德权,李波,马昆. 乳腺癌癌旁组织特异性表达基因分析[J]. 遗传, 2019, 41(7): 625-633. |
[6] |
余同露,蔡栋梁,朱根凤,叶晓娟,闵太善,陈红岩,卢大儒,陈浩明. CSN4基因干扰对乳腺癌MDA-MB-231细胞增殖和凋亡的影响[J]. 遗传, 2019, 41(4): 318-326. |
[7] |
孙书国, 吴世安, 张雷. Hippo信号通路在果蝇遗传学研究中的发现与扩展[J]. 遗传, 2017, 39(7): 537-545. |
[8] |
吉新彦, 钟国轩, 赵斌. 哺乳动物Hippo信号通路分子机制研究进展[J]. 遗传, 2017, 39(7): 546-567. |
[9] |
张平平,佟鑫,张天乐,黎子琛,龚清秋. 植物Hippo信号通路研究进展[J]. 遗传, 2017, 39(7): 568-575. |
[10] |
顾远, 张雷, 余发星. Hippo信号通路在肠道稳态、再生及癌变过程中的作用及机制[J]. 遗传, 2017, 39(7): 588-596. |
[11] |
付思玲,赵婉滢,张雯婧,宋海,季红斌,汤楠. Hippo信号通路在肺发育、再生和疾病中的功能[J]. 遗传, 2017, 39(7): 597-606. |
[12] |
包笑妹, 何晴, 王莹, 黄智慧, 袁增强. Hippo/YAP信号通路在神经系统中的作用及机制研究进展[J]. 遗传, 2017, 39(7): 630-641. |
[13] |
周欣,李伟芸,王红艳. MST1/2调控先天免疫的功能和机制[J]. 遗传, 2017, 39(7): 642-649. |
[14] |
余淑娟,耿晶,陈兰芬. Hippo信号通路调控免疫细胞的功能[J]. 遗传, 2017, 39(7): 650-658. |
[15] |
胡立桥,周兆才,田伟. Hippo信号通路结构生物学研究进展[J]. 遗传, 2017, 39(7): 659-674. |
|